Abstract: Poly(ADP-ribose) polymerase (PARP) is a family of proteins that play a crucial role in diverse cellular processes, including DNA repair, cell death, and changes in chromatin structure. PARP inhibitors (PARPi) have been recognized as notable agents in the realm of anticancer therapeutics owing to their capacity to specifically impact DNA repair pathways, thereby inducing targeted death of cancerous cells, particularly in cancers with homologous recombination deficiency (HRD). These inhibitors have been approved for the treatment of several cancers, such as ovarian, breast, and pancreatic cancers. Despite their promising therapeutic attributes, developing resistance to PARPi presents a formidable obstacle, curtailing their overall efficacy. This article presents a comprehensive description of the potential mechanisms related to PARPi resistance, an in-depth study of potential strategies to overcome resistance, and an assessment of the therapeutic potential of the PARPi in combination with alternative therapies.

PARP抑制剂在癌症治疗中的未来：通过联合疗法克服耐药性并提高疗效

[1]AbidaW, CampbellD, PatnaikA, et al., 2019. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (MCRPC): updated analyses. Ann Oncol, 30(S5):v327-v328.

[2]Amarante-MendesGP, AdjemianS, BrancoLM, et al., 2018. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol, 9:2379.

[3]AntolinAA, AmeratungaM, BanerjiU, et al., 2020. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep, 10:2585.

[4]ArmstrongN, RyderS, ForbesC, et al., 2019. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol, 11:543-561.

[5]AzarmK, SmithS, 2020. Nuclear PARPs and genome integrity. Genes Dev, 34(5-6):285-301.

[6]BaerMR, KoganAA, BentzenSM, et al., 2022. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia. Clin Cancer Res, 28(7):1313-1322.

[7]BeckC, BoehlerC, Guirouilh BarbatJ, et al., 2014. PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. Nucleic Acids Res, 42(9):5616-5632.

[8]BertiM, CortezD, LopesM, 2020. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress. Nat Rev Mol Cell Biol, 21(10):633-651.

[9]BhuttaZA, GoRE, ChoiKC, 2024. Effect of punicalagin on the autophagic cell death in triple-negative breast cancer cells. Toxicol Res, 10(4):585-598.

[10]BianCJ, ZhangC, LuoT, et al., 2019. NADP⁺ is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun, 10:693.

[11]BoumehiraAZ, AkchicheYF, CherfiW, et al., 2022. Metabolomics approaches for early cancer diagnosis: a review. Asian J Agric Biol, (4):202012566.

[12]BoussiosS, KarihtalaP, MoschettaM, et al., 2020. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs, 38(1):181-193.

[13]CallenE, ZongDL, WuW, et al., 2020. 53BP1 enforces distinct pre- and post-resection blocks on homologous recombination. Mol Cell, 77(1):26-38.e7.

[14]CaraccioloD, RiilloC, ArbitrioM, et al., 2020. Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. Int J Cancer, 147(10):2658-2668.

[15]CaraccioloD, RiilloC, di MartinoMT, et al., 2021. Alternative non-homologous end-joining: error-prone DNA repair as cancer’s Achilles’ heel. Cancers (Basel), 13(6):1392.

[16]ChambonP, WeillJD, MandelP, 1963. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun, 11(1):39-43.

[17]ChanWY, BrownLJ, ReidL, et al., 2021. PARP inhibitors in melanoma—an expanding therapeutic option? Cancers (Basel), 13(18):4520.

[18]ChaudhariS, WareAP, JayaramP, et al., 2021. Apurinic/Apyrimidinic Endonuclease 2 (APE2): an ancillary enzyme for contextual base excision repair mechanisms to preserve genome stability. Biochimie, 190:70-90.

[19]ChoiYE, MeghaniK, BraultME, et al., 2016. Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep, 14(3):429-439.

[20]ClementsKE, SchleicherEM, ThakarT, et al., 2020. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun, 11:6118.

[21]ColemanRL, OzaAM, LorussoD, et al., 2017. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10106):1949-1961.

[22]CongK, PengM, KousholtAN, et al., 2021. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell, 81(15):3128-3144.e7.

[23]ConstantinouS, 2019. Mechanisms of human RAD51 regulation by RAD52 and BRCA2. PhD Thesis, University of Cambridge, UK.

[24]CurtinNJ, SzaboC, 2020. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov, 19(10):711-736.

[25]de BonoJ, MateoJ, FizaziK, et al., 2020. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med, 382(22):2091-2102.

[26]de KrijgerI, BoersmaV, JacobsJJL, 2021. REV7: jack of many trades. Trends Cell Biol, 31(8):686-701.

[27]DiasMP, MoserSC, GanesanS, et al., 2021. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol, 18(12):773-791.

[28]DrewY, PensonRT, O'MalleyDM, et al., 2020. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol, 31(S4):S615-S616.

[29]EttlJ, QuekRGW, LeeKH, et al., 2018. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol, 29(9):1939-1947.

[30]FaragoAF, YeapBY, StanzioneM, et al., 2019. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov, 9(10):1372-1387.

[31]FaraoniI, GrazianiG, 2018. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers (Basel), 10(12):487.

[32]FaraoniI, GiansantiM, VosoMT, et al., 2019. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. Biochem Pharmacol, 167:133-148.

[33]FattahF, LeeEH, WeisenselN, et al., 2010. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genetics, 6(2):e1000855.

[34]FriedlanderM, MatulonisU, GourleyC, et al., 2018. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer, 119(9):1075-1085.

[35]FujiwaraK, VergoteIB, SehouliJ, et al., 2019. ENGOT-ov43/KEYLYNK-001: a phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer. Ann Oncol, 30(S9):ix89.

[36]GandagliaG, LeniR, BrayF, et al., 2021. Epidemiology and prevention of prostate cancer. Eur Urol Oncol, 4(6):877-892.

[37]GaymesTJ, MohamedaliAM, PattersonM, et al., 2013. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica, 98(9):1397-1406.

[38]GeorgeA, KayeS, BanerjeeS, 2017. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol, 14(5):284-296.

[39]GiriAK, AittokallioT, 2019. DNMT inhibitors increase methylation in the cancer genome. Front Pharmacol, 10:385.

[40]GiudiceE, GentileM, SalutariV, et al., 2022. PARP inhibitors resistance: mechanisms and perspectives. Cancers (Basel), 14(6):1420.

[41]GolanT, HammelP, ReniM, et al., 2019. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med, 381(4):317-327.

[42]GonçalvesA, BertucciA, BertucciF, 2020. PARP inhibitors in the treatment of early breast cancer: the step beyond? Cancers (Basel), 12(6):1378.

[43]González-MartínA, PothuriB, VergoteI, et al., 2019. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 381(25):2391-2402.

[44]GornsteinEL, SandefurS, ChungJH, et al., 2018. BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy. Clin Breast Cancer, 18(2):184-188.

[45]HanHS, DiérasV, RobsonM, et al., 2018. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol, 29(1):154-161.

[46]HanY, YuXP, LiSQ, et al., 2020. New perspectives for resistance to PARP inhibitors in triple-negative breast cancer. Front Oncol, 10:578095.

[47]HanzlikovaH, CaldecottKW, 2019. Perspectives on PARPs in S phase. Trends in Genetics, 35(6):412-422.

[48]HanzlikovaH, GittensW, KrejcikovaK, et al., 2017. Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res, 45(5):2546-2557.

[49]HarrisionD, GravellsP, ThompsonR, et al., 2020. Poly(ADP-ribose) glycohydrolase (PARG) vs. poly(ADP-ribose) polymerase (PARP) ‒ function in genome maintenance and relevance of inhibitors for anti-cancer therapy. Front Mol Biosci, 7:191.

[50]HarterP, TrillschF, OkamotoA, et al., 2023. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (PTS) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol, 41(17_suppl):LBA5506.

[51]HaynesB, MuraiJ, LeeJM, 2018. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev, 71:1-7.

[52]HeJ, FortunatiE, LiuDX, et al., 2021. Pleiotropic roles of ABC transporters in breast cancer. Int J Mol Sci, 22(6):3199.

[53]HeekeAL, PishvaianMJ, LynceF, et al., 2018. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol, 2:1-13.

[54]HeekeAL, PishvaianM, WangHK, et al., 2020. Abstract OT2-03-04: a trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: the TALAVE study. Cancer Res, 80(4_suppl):OT2-04.

[55]HiguchiF, NagashimaH, NingJF, et al., 2020. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin Cancer Res, 26(7):1690-1699.

[56]HirotaK, OokaM, ShimizuN, et al., 2022. XRCC1 counteracts poly(ADP ribose) polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. Genes Cells, 27(5):331-344.

[57]HjortkjærM, KanstrupH, JakobsenA, et al., 2018. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treat Res Commun, 14:7-12.

[58]HopkinsTA, ShiY, RodriguezLE, et al., 2015. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res, 13(11):1465-1477.

[59]HuXY, ZhangJF, ZhangY, et al., 2022. Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: advances, challenges, and opportunities. Eur J Med Chem, 230:114094.

[60]JonuscheitS, JostT, GajdošováF, et al., 2021. PARP inhib

[61]itors talazoparib and niraparib sensitize melanoma cells to ionizing radiation. Genes, 12(6):849.

[62]KeeY, D'AndreaAD, 2010. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev, 24(16):1680-1694.

[63]KimSJ, LeeK, ParkJ, et al., 2023. CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer. Toxicol Res, 39(1):61-69.

[64]KonstantinopoulosPA, WaggonerS, VidalGA, et al., 2019. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncology, 5(8):1141-1149.

[65]KoppensteinerR, SamartzisEP, NoskeA, et al., 2014. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE, 9(6):e100041.

[66]KozonoDE, StinchcombeTE, SalamaJK, et al., 2021. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 159:56-65.

[67]KubalanzaK, KonecnyGE, 2020. Mechanisms of PARP inhibitor resistance in ovarian cancer. Curr Opin Obstet Gynecol, 32(1):36-41.

[68]KumariN, 2023. A ligase IV/XRCC4-dependent single strand break repair pathway for the maintenance of A/T-rich regions during DNA replication in mammals. PhD Dissemination, Indian Institute of Science, Bangalore, Indian.

[69]LairdJH, LokBH, MaJ, et al., 2018. Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts. Clin Cancer Res, 24(20):5143-5152.

[70]LakomyDS, UrbauerDL, WestinSN, et al., 2020. Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. Clin Transl Radiat Oncol, 21:56-61.

[71]LaspataN, MuoioD, FouquerelE, 2024. Multifaceted role of PARP1 in maintaining genome stability through its binding to alternative DNA structures. J Mol Biol, 436(1):168207.

[72]LeD, GelmonKA, 2018. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. Expert Rev Clin Pharmacol, 11(9):833-839.

[73]LeeYC, LeeYC, LiCY, et al., 2020. BRCA1 and BRCA2 gene mutations and lung cancer risk: a meta-analysis. Medicina, 56(5):212.

[74]LiSY, WangLL, WangYY, et al., 2022. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J Hematol Oncol, 15(1):147-147.

[75]LiT, ChenZJ, 2018. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med, 215(5):1287-1299.

[76]LinKK, HarrellMI, OzaAM, et al., 2019. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov, 9(2):210-219.

[77]LittonJK, HurvitzSA, MinaLA, et al., 2020. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the embraca trial. Ann Oncol, 31(11):1526-1535.

[78]LiuQ, FangLM, WuCJ, 2022. Alternative splicing and isoforms: from mechanisms to diseases. Genes (Basel), 13(3):401.

[79]LorussoP, PilatMJP, Santa-MariaCA, et al., 2020. Trial in progress: a phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer. J Clin Oncol, 38(15_suppl):TPS1102.

[80]LuYJ, ChanYT, TanHY, et al., 2020. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer, 19:7.

[81]LuoJ, DaiXC, HuH, et al., 2020. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol, 146(3):721-737.

[82]LykoF, 2018. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet, 19(2):81-92.

[83]MaharjanA, GautamR, AcharyaM, et al., 2023. Association of immunotoxicological indices with lung cancer biomarkers in poultry, grape, and rose farming workers. Toxicol Res, 39(4):739-747.

[84]MatanesE, López-OzunaVM, OcteauD, et al., 2021. Inhibition of poly ADP-ribose glycohydrolase sensitizes ovarian cancer cells to poly ADP-ribose polymerase inhibitors and platinum agents. Front Oncol, 11:745981.

[85]MateoJ, PortaN, BianchiniD, et al., 2020. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol, 21(1):162-174.

[86]Maya-MendozaA, MoudryP, Merchut-MayaJM, et al., 2018. High speed of fork progression induces DNA replication stress and genomic instability. Nature, 559(7713):279-284.

[87]McCarthy-LeoC, DarwicheF, TainskyMA, 2022. DNA repair mechanisms, protein interactions and therapeutic targeting of the MRN complex. Cancers (Basel), 14(21):5278.

[88]MirzaMR, MonkBJ, HerrstedtJ, et al., 2016. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med, 375(22):2154-2164.

[89]MoorN, Vasil’evaI, LavrikO, 2020. Functional role of N-terminal extension of human AP endonuclease 1 in coordination of base excision DNA repair via protein‒protein interactions. Int J Mol Sci, 21(9):3122.

[90]MooreKN, SecordAA, GellerMA, et al., 2019. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol, 20(5):636-648.

[91]MouwKW, GoldbergMS, KonstantinopoulosPA, et al., 2017. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov, 7(7):675-693.

[92]MuraiJ, HuangSYN, DasBB, et al., 2012. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res, 72(21):5588-5599.

[93]NoordermeerSM, van AttikumH, 2019. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol, 29(10):820-834.

[94]OhM, AlkhushaymN, FallatahS, et al., 2019. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate, 79(8):880-895.

[95]OzaAM, TinkerAV, OakninA, et al., 2017. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2. Gynecol Oncol, 147(2):267-275.

[96]PatelAG, SarkariaJN, KaufmannSH, 2011. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA, 108(8):3406-3411.

[97]PovedaA, FloquetA, LedermannJA, et al., 2021. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-OV21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol, 22(5):620-631.

[98]PreissJ, SchlaegerR, HilzH, 1971. Specific inhibition of poly adpribose polymerase by thymidine and nicotinamide in HeLa cells. FEBS Lett, 19(3):244-246.

[99]RahibL, WehnerMR, MatrisianLM, et al., 2021. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open, 4(4):e214708.

[100]RaimundoL, CalheirosJ, SaraivaL, 2021. Exploiting DNA damage repair in precision cancer therapy: BRCA1 as a prime therapeutic target. Cancers (Basel), 13(14):3438.

[101]Ray ChaudhuriA, NussenzweigA, 2017. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol, 18(10):610-621.

[102]Ray-CoquardI, PautierP, PignataS, et al., 2019. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med, 381(25):2416-2428.

[103]RobsonM, ImSA, SenkusE, et al., 2017. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med, 377(6):523-533.

[104]SachdevE, TabatabaiR, RoyV, et al., 2019. PARP inhibition in cancer: an update on clinical development. Targ Onco, 14(6):657-679.

[105]SavilleKM, 2022. Role of PARP1 and NAD⁺ bioavailability in base excision and single-strand break repair. PhD Thesis, University of South Alabama, United States. https://jagworks.southalabama.edu/theses_diss/98

[106]ShenJF, ZhaoW, JuZL, et al., 2019. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res, 79(2):311-319.

[107]ShengY, XuME, LiCY, et al., 2018. Nm23-H1 is involved in the repair of ionizing radiation-induced DNA double-strand breaks in the A549 lung cancer cell line. BMC Cancer, 18:710.

[108]ShibataA, JeggoPA, 2021. ATM’s role in the repair of DNA double-strand breaks. Genes (Basel), 12(9):1370.

[109]ShortNJ, RyttingME, CortesJE, 2018. Acute myeloid leukaemia. Lancet, 392(10147):593-606.

[110]ShortNJ, DombretH, AdèsL, et al., 2022. The evolution of research and therapy with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: new directions for old drugs. Cancer J, 28(1):29-36.

[111]ShroffRT, HendifarA, McWilliamsRR, et al., 2018. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol, 2:1-15.

[112]SinghDD, ParveenA, YadavDK, 2021. Role of PARP in TNBC: mechanism of inhibition, clinical applications, and resistance. Biomedicines, 9(11):1512.

[113]SishcBJ, DavisAJ, 2017. The role of the core non-homologous end joining factors in carcinogenesis and cancer. Cancers (Basel), 9(7):81.

[114]SizemoreST, MohammadR, SizemoreGM, et al., 2018. Synthetic lethality of PARP inhibition and ionizing radiation is p53-dependent. Mol Cancer Res, 16(7):1092-1102.

[115]SomloG, FrankelPH, ArunBK, et al., 2017. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res, 23(15):4066-4076.

[116]StavropoulouV, PetersAHFM, SchwallerJ, 2018. Aggressive leukemia driven by MLL-AF9. Mol Cell Oncol, 5(3):e1241854.

[117]SungH, FerlayJ, SiegelRL, et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209-249.

[118]Svetec MiklenićM, SvetecIK, 2021. Palindromes in DNA—a risk for genome stability and implications in cancer. Int J Mol Sci, 22(6):2840.

[119]SwisherEM, AghajanianC, O'MalleyDM, et al., 2022. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the phase 3 VELIA/GOG-3005 study. Gynecol Oncol, 164(2):245-253.

[120]TuliR, ShiaoSL, NissenN, et al., 2019. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine, 40:375-381.

[121]ValabregaG, ScottoG, TuninettiV, et al., 2021. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci, 22(8):4203.

[122]van den BulkJ, VerdegaalEME, deMiranda NFCC, 2018. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol, 8(6):180037.

[123]VinayakS, TolaneySM, SchwartzbergL, et al., 2019. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol, 5(8):1132-1140.

[124]VosS, van DiestPJ, MoelansCB, 2018. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: mutually exclusive, or not? Crit Rev Oncol Hematol, 127:29-41.

[125]WangJJ, ZhuX, DangL, et al., 2022. Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation. J Clin Invest, 132(4):e149526.

[126]WangL, YangCY, XieCY, et al., 2019. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci, 110(3):1064-1075.

[127]WangML, WuWZ, WuWQ, et al., 2006. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res, 34(21):6170-6182.

[128]XiaMY, GuoZG, HuZG, 2021. The role of PARP inhibitors in the treatment of prostate cancer: recent advances in clinical trials. Biomolecules, 11(5):722.

[129]YarchoanM, HopkinsA, JaffeeEM, 2017. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med, 377(25):2500-2501.

[130]YusohNA, AhmadH, GillMR, 2020. Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy. ChemMedChem, 15(22):2121-2135.

[131]ZhangJH, StevensMFG, BradshawTD, 2012. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol, 5(1):102-114.

[132]ZhaoQ, LanTL, SuS, et al., 2019. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem Commun, 55(3):369-372.